Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase–producing Escherichia coli or Klebsiella pneumoniae

Lee, Nan-Yao; Huang, Wei Han; Tsui, Ko Chung; Hsueh, Po-Ren; Ko, Wen–Chien

doi:10.1016/j.diagmicrobio.2010.12.008

Cited by 33 publications

(20 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In another recently published study of 351 patients with bacteremia due to ESBL-producing E. coli or K. pneumoniae, 30-day survival was greater in carbapenem-than noncarbapenem-treated patients, and lower in cephalosporin-treated patients than in those not treated with cephalosporins [7]. A further ana lysis of the data showed that ertapenem was noninferior to imipenem or meropenem.…”

Section: Esbl Producers and Mortalitymentioning

confidence: 80%

Developments in Antimicrobial Resistance and Treatment

Bryan¹

2011

Future Microbiol.

View full text Add to dashboard Cite

On World Health Day (7 April 2011), the WHO urged rapid and concerted action to safeguard today's antimicrobial drug treatments against resistance, and published a package of policies for governments and their national partners to combat the growing threat. So the timing could not have been better for leading scientists and researchers to discuss the latest developments in antimicrobial resistance and treatment at this year's International Symposium on Antimicrobial Agents and Resistance, held in a region of the world - Asia-Pacific - that is facing some of the greatest challenges from extended-spectrum β-lactamase-producing bacteria.

show abstract

Section: Esbl Producers and Mortalitymentioning

confidence: 80%

Developments in Antimicrobial Resistance and Treatment

Bryan¹

2011

Future Microbiol.

View full text Add to dashboard Cite

show abstract

“…Carbapenems are still one of the most widely used therapeutic options for A. baumannii , as long as the isolates remain susceptible to these drugs [5]. However, the incidence CRAB infection is increasing in several countries [1], [2], [6], and a major factor that has been suggested to contribute to this growing crisis is the increased use of carbapenems to treat infections caused by extended-spectrum β-lactamase (ESBL)-producing or Amp-C β-lactamase-producing gram-negative bacteria [7]–[10].…”

Section: Introductionmentioning

confidence: 99%

Effects of Group 1 versus Group 2 Carbapenems on the Susceptibility of Acinetobacter baumannii to Carbapenems: A Before and After Intervention Study of Carbapenem-Use Stewardship

Yoon¹,

Yang

Lee

2014

PLoS ONE

View full text Add to dashboard Cite

ObjectiveAntimicrobial stewardship programs have been proposed for reducing bacterial resistance in the hospital environment. The purpose of this study was to investigate the impact of a carbapenem-use stewardship program on the susceptibility of Acinetobacter baumannii to Group 2 carbapenems.MethodsA before and after intervention study was conducted at a university hospital from September 2008 to February 2013. Three study periods were defined: Phase I, pre-intervention (months 1–18); Phase II, a postintervention period during which ertapenem use was mandated but carbapenem use was not restricted (months 19–36); and Phase III, a postintervention period during which Group 2 carbapenem use was restricted (months 37–54).ResultsDuring the study period, intervention resulted in diminished consumption of Group 2 carbapenems (antimicrobial use density (AUD): 21.3±6.0 in Phase I, 18.8±6.0 in Phase II, 16.1±4.4 in Phase III; P = 0.028) and increased consumption of ertapenem (AUD: 2.7±1.7 in Phase I, 7.2±4.5 in Phase II, 9.1±5.3 in Phase III; P<0.001). The use of autoregressive-error models showed that in contrast with ertapenem use, the use of Group 2 carbapenem during the previous one month was positively and significantly associated with a subsequent increase in the proportion of carbapenem-resistant A. baumannii (CRAB) (P = 0.031).ConclusionsImplementing a carbapenem-use stewardship program featuring the preferential use of ertapenem for treating appropriate indications of infection resulted in reduced use of Group 2 carbapenems and had a positive impact on the susceptibility of A. baumannii to carbapenems. This approach could be integrated into CRAB-control strategies in hospitals.

show abstract

“…Resistance to Penicillins and β-lactams has been on the increase over the years (Mortensen et al, 2016;Yoon et al, 2017). Some gram negative bacteria have been studied to produce intrinsic chromosomal encoded enzymes that facilitates resistance to Penicillins and beta-lactams (Lee et al, 2011;Matsumura et al, 2015). It was observed that the pH of the extracts was highly acidic with the ethanol extract being the most acidic.…”

Section: Discussionmentioning

confidence: 99%

Susceptibility of Selected Multi-Drug Resistant Clinical Isolates to Different Leaf Extracts of Senna alata

et al. 2018

View full text Add to dashboard Cite

The present study evaluated the antibacterial effects of the methanolic, ethanolic and aqueous extracts of Senna alata leaves. The extracts were tested using agar well diffusion method against selected clinical isolates: Salmonella typhi, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus and Klebsiella pneumoniae. Antibiogram profile of the isolates deduced by disc diffusion method confirmed that the methanolic extract inhibited the growth of all tested organisms except for Klebsiella pneumoniae, which also showed no sensitivity to the ethanolic extract. There was no inhibition observed for the aqueous extract against all the tested organisms, indicating that the methanolic extract of the plant was more potent than the aqueous extract. Inhibitory activities were observed for gentamicin, ofloxacin and erythromycin against Staphylococcus aureus and Escherichia coli. No inhibitory activity was observed in all the antibiotics against Pseudomonas aeruginosa. In Klebsiella pneumoniae, inhibition was only observed in ofloxacin. The activity of both the methanolic and ethanolic extract of Senna alata was optimal under different concentrations, but gradually diminished as the concentration was adjusted. The activity of the plant extracts against the selected bacteria is an indication of the presence of broad spectrum bioactive compounds which could be explored in the therapy of bacterial infections.

show abstract

Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase–producing Escherichia coli or Klebsiella pneumoniae

Cited by 33 publications

References 13 publications

Developments in Antimicrobial Resistance and Treatment

Developments in Antimicrobial Resistance and Treatment

Effects of Group 1 versus Group 2 Carbapenems on the Susceptibility of Acinetobacter baumannii to Carbapenems: A Before and After Intervention Study of Carbapenem-Use Stewardship

Susceptibility of Selected Multi-Drug Resistant Clinical Isolates to Different Leaf Extracts of Senna alata

Contact Info

Product

Resources

About